REG - SkinBioTherapeutics - Independent Investigation Appointment

SkinbiotherapeuticsAnnouncement

20/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260220:nRST7469Ta&default-theme=true

RNS Number : 7469T  SkinBioTherapeutics PLC  20 February 2026

 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

 

Independent Investigation Appointment

 

20 February 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the
life science business focused on skin health, announces that it has appointed
its new Non-Executive Director and Chair of the Audit Committee, Alyson
Levett, to oversee the continuing investigation process on behalf of the
Board. It has also appointed FRP Advisory to undertake an independent,
forensic review into the matters outlined by the Company on Monday, 16
February. Existing external legal and professional advisers will also support
the process, as necessary.

Alyson Levett, Non-Executive Director and Chair of the Audit Committee of
SkinBioTherapeutics, said: "The Board's aim has always been to act quickly -
undertaking an investigation whilst maintaining business continuity and
minimising disruption. FRP Advisory can help us expedite our investigation and
enable us to issue the HY results as soon as possible in the confidence that
all issues have been identified. The senior leadership team can then return
their focus to running and growing the business."

The Company will continue to provide updates as appropriate.

 

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  ir@skinbiotix.com
 Martin Hunt, Executive Chairman

Emily Bertram, CFO
 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

Philip Davies

James Todd

Patrick Weaver
 Vigo Consulting                                          +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare
(SkinBiotix(®)) and food supplements that harness the gut-skin axis
(AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where
SkinBiotix(®) is being used as an active skin ingredient with the Croda trade
name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting
the symptoms of inflammatory skin conditions, being sold directly and via
Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skincare and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.SkinBioTherapeutics.com
(http://www.skinbiotherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBGDDDSBDGLC



            Copyright 2019 Regulatory News Service, all rights reserved